Institutul National de Boli Infectioase "Prof.Dr. Matei Bals"

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Hepatitis B9 trials
• HIV6 trials
• Bronchiectasis1 trial
• Cystic fibrosis1 trial
• Diabetic foot ulcer1 trial
• Hepatitis C1 trial
• Liver cirrhosis1 trial

Phase

• Phase 26 trials
• Phase 14 trials
• Phase 34 trials
• Phase 1/22 trials
• Phase 2/32 trials

Status

• Completed12 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials
• Recruiting1 trial
• Suspended1 trial

Lead sponsor

• Gilead Sciences Inc.2 trials
• GlaxoSmithKline2 trials
• Merck Sharp & Dohme LLC2 trials
• Vir Biotechnology, Inc.2 trials
• Aligos Therapeutics Inc.1 trial
• and 9 more

Running trials

• Recruiting

  Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

  2026-526026-40-00· Phase 2/3· Gilead Sciences Inc.· Source

• Not yet recruiting

  A continued access study for ParticipAnts Transitioning from ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies for HIV treatment (PATH) Appendix: BRIGHTE

  2025-522910-21-00· Phase 3· Viiv Healthcare UK Limited· Source

• Recruiting

  Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects with Chronic Hepatitis B (B-SUPREME)

  2025-521178-33-00· Phase 2· Aligos Therapeutics Inc.· Source

• Active, not recruiting

  Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV2 recruiting
• Hepatitis B1 recruiting

Closed trials

• Completed

  MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

  NCT07042945· Phase 1· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

  2024-512505-66-00· Phase 2/3· Gilead Sciences Inc.· Source

• Completed

  Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa) (NOPA)

  2023-508706-23-00· Phase 1/2· Thirty Respiratory Limited· Source

• Completed

  A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection

  2024-511051-18-00· Phase 1· Assembly Biosciences Inc.· Source

• Completed

  Open-Label Study of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab in Subjects with Chronic HBV Infection

  NCT06245291· Phase 2· Arbutus Biopharma Inc.· Source

• Completed

  Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

  NCT05960240· Phase 1· Arbutus Biopharma Corporation· Source

• Completed

  A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

  NCT05904470· Phase 2· Atea Pharmaceuticals, Inc.· Source

• Completed

  A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

  NCT05612581· Phase 1/2· Vir Biotechnology, Inc.· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· Phase 3· GlaxoSmithKline· Source

• Completed

  MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

  NCT05494736· Phase 1· Merck Sharp & Dohme LLC· Source

• Recruiting

  Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

  NCT05369052· Phase 3· MicuRx· Source

• Completed

  Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

  NCT04856085· Phase 2· Vir Biotechnology, Inc.· Source